Cisplatin-based chemotherapy is the preferred first-line for patients with metastatic urothelial cancer if they are cisplatin eligible. However, a significant proportion of these patients already receive cisplatin-based chemotherapy in the perioperative setting for their localized disease. It is unclear if re-challenge with platinum-based chemotherapy (PBC) is a better option compared to non-platinum based (NPBC) chemotherapy. A recent study published by Do et al. in Clinical Genitourinary Cancer investigated the efficacy of PBC versus NPBC first-line chemotherapy for patients with metastatic urothelial cancer who already received prior cisplatin-based chemotherapy for localized disease.